Test 106

The 1:00pm final claims review is complete. Marcus Vail asked whether Helio Start’s two qualifying mature cohorts should create Q2 forecast credit. I separated the operating gate from a commercial result: the cohorts permit consideration of a capped proposal, but there is still no paid traffic, approved budget, or acquisition evidence. The Helio Start row also still lacks the exact cohort start and end dates required by the January 6 readiness gate, so I kept it `not board-ready` and excluded it from the board operating-evidence section rather than weakening the gate. Helio Start remains organic-only through March 31, and the cleared proposal gate does not authorize paid traffic, budget, acquisition claims, pipeline treatment, or forecast credit. Expansion Assist remains descriptive because it has no randomized control. The November 26-through-February 28 pricing-page coverage remains post-rollout continuity evidence rather than a second causal test, and the January 1-through-February 28 CS auto-nudge lane remains limited to system-control performance. Owen, Ines, and Daniela confirmed the applicable source and limit sections for those three board-ready lanes. Tomás approved my operating-evidence section containing those three lanes without adding a Helio Start forecast claim. Update `Quarterly board operating evidence intake — Q1 2026` with the final review decision, Tomás’s approved three-lane section, the final claims and limits, and Helio Start’s continuing exclusion and `not board-ready` status.

The 1:00pm final claims review is complete. Marcus Vail asked whether Helio Start’s two qualifying mature cohorts should create Q2 forecast credit. I separated the operating gate from a commercial result: the cohorts permit consideration of a capped proposal, but there is still no paid traffic, approved budget, or acquisition evidence. The Helio Start row also still lacks the exact cohort start and end dates required by the January 6 readiness gate, so I kept it `not board-ready` and excluded it from the board operating-evidence section rather than weakening the gate. Helio Start remains organic-only through March 31, and the cleared proposal gate does not authorize paid traffic, budget, acquisition claims, pipeline treatment, or forecast credit. Expansion Assist remains descriptive because it has no randomized control. The November 26-through-February 28 pricing-page coverage remains post-rollout continuity evidence rather than a second causal test, and the January 1-through-February 28 CS auto-nudge lane remains limited to system-control performance. Owen, Ines, and Daniela confirmed the applicable source and limit sections for those three board-ready lanes. Tomás approved my operating-evidence section containing those three lanes without adding a Helio Start forecast claim. Update `Quarterly board operating evidence intake — Q1 2026` with the final review decision, Tomás’s approved three-lane section, the final claims and limits, and Helio Start’s continuing exclusion and `not board-ready` status.

The 1:00pm final claims review is complete. Marcus Vail asked whether Helio Start’s two qualifying mature cohorts should create Q2 forecast credit. I separated the operating gate from a commercial result: the cohorts permit consideration of a capped proposal, but there is still no paid traffic, approved budget, or acquisition evidence. The Helio Start row also still lacks the exact cohort start and end dates required by the January 6 readiness gate, so I kept it `not board-ready` and excluded it from the board operating-evidence section rather than weakening the gate. Helio Start remains organic-only through March 31, and the cleared proposal gate does not authorize paid traffic, budget, acquisition claims, pipeline treatment, or forecast credit. Expansion Assist remains descriptive because it has no randomized control. The November 26-through-February 28 pricing-page coverage remains post-rollout continuity evidence rather than a second causal test, and the January 1-through-February 28 CS auto-nudge lane remains limited to system-control performance. Owen, Ines, and Daniela confirmed the applicable source and limit sections for those three board-ready lanes. Tomás approved my operating-evidence section containing those three lanes without adding a Helio Start forecast claim. Update `Quarterly board operating evidence intake — Q1 2026` with the final review decision, Tomás’s approved three-lane section, the final claims and limits, and Helio Start’s continuing exclusion and `not board-ready` status.

The July 10 final claims review is complete. Marcus Vail asked whether the paid Helio Start cohort’s 39-of-50 day-7 first-integration result could support a growth or forecast statement. I kept it out because the fixed 50-workspace cohort still lacks complete day-90 paid-active status, refund-adjusted collected cash, and account-level support effort. Tomás approved a three-lane Q2 operating-evidence section: Expansion Assist remains descriptive with no causal, revenue, pipeline, or forecast treatment; pricing-page path quality remains post-rollout continuity evidence rather than a new causal result; and CS auto-nudge evidence remains limited to system-control performance. Helio Start is excluded from the approved Q2 section until its mature window closes, with no acquisition or forecast claim added. This closes the Q2 final-claims decision; the paid-pilot day-90 outcome matter remains open separately. Update `Q2 board-evidence source-completeness checkpoint — May 13` with the completed July 10 review, the three approved bounded lanes, and the Helio Start exclusion pending complete day-90 outcomes.

The July 10 final claims review is complete. Marcus Vail asked whether the paid Helio Start cohort’s 39-of-50 day-7 first-integration result could support a growth or forecast statement. I kept it out because the fixed 50-workspace cohort still lacks complete day-90 paid-active status, refund-adjusted collected cash, and account-level support effort. Tomás approved a three-lane Q2 operating-evidence section: Expansion Assist remains descriptive with no causal, revenue, pipeline, or forecast treatment; pricing-page path quality remains post-rollout continuity evidence rather than a new causal result; and CS auto-nudge evidence remains limited to system-control performance. Helio Start is excluded from the approved Q2 section until its mature window closes, with no acquisition or forecast claim added. This closes the Q2 final-claims decision; the paid-pilot day-90 outcome matter remains open separately. Update `Q2 board-evidence source-completeness checkpoint — May 13` with the completed July 10 review, the three approved bounded lanes, and the Helio Start exclusion pending complete day-90 outcomes.

The July 10 final claims review is complete. Marcus Vail asked whether the paid Helio Start cohort’s 39-of-50 day-7 first-integration result could support a growth or forecast statement. I kept it out because the fixed 50-workspace cohort still lacks complete day-90 paid-active status, refund-adjusted collected cash, and account-level support effort. Tomás approved a three-lane Q2 operating-evidence section: Expansion Assist remains descriptive with no causal, revenue, pipeline, or forecast treatment; pricing-page path quality remains post-rollout continuity evidence rather than a new causal result; and CS auto-nudge evidence remains limited to system-control performance. Helio Start is excluded from the approved Q2 section until its mature window closes, with no acquisition or forecast claim added. This closes the Q2 final-claims decision; the paid-pilot day-90 outcome matter remains open separately. Update `Q2 board-evidence source-completeness checkpoint — May 13` with the completed July 10 review, the three approved bounded lanes, and the Helio Start exclusion pending complete day-90 outcomes.

The July 10 final claims review is complete. Marcus Vail asked whether the paid Helio Start cohort’s 39-of-50 day-7 first-integration result could support a growth or forecast statement. I kept it out because the fixed 50-workspace cohort still lacks complete day-90 paid-active status, refund-adjusted collected cash, and account-level support effort. Tomás approved a three-lane Q2 operating-evidence section: Expansion Assist remains descriptive with no causal, revenue, pipeline, or forecast treatment; pricing-page path quality remains post-rollout continuity evidence rather than a new causal result; and CS auto-nudge evidence remains limited to system-control performance. Helio Start is excluded from the approved Q2 section until its mature window closes, with no acquisition or forecast claim added. This closes the Q2 final-claims decision; the paid-pilot day-90 outcome matter remains open separately. Update `Q2 board-evidence source-completeness checkpoint — May 13` with the completed July 10 review, the three approved bounded lanes, and the Helio Start exclusion pending complete day-90 outcomes.